



**FOLEY
HOAG**
ATTORNEYS AT LAW

RECEIVED

Jennifer K. Holmes, Ph.D.
Boston Office
617.832.1770
jholmes@foleyhoag.com

November 19, 2001

FEB 05 2002

TECH CENTER 1600/2900

Box Sequence Listing
Assistant Commissioner of Patents
Washington, DC 20231
Box Sequence Listing

RECEIVED
FEB 07 2002
OFFICE OF THE
DEPUTY ASSISTANT
COMMISSIONER OF
PATENTS

Re: U.S. Patent Application No.: 09/575,580
Entitled: *Calcipressins: Endogenous Inhibitors of Calcineurin, Uses and
Reagents Related Thereto*
Filed: May 22, 2000
By: McKeon et al.
Atty Ref: HMV-048.01

Dear Sir:

In response to the "Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed
September 18, 2001 in the above-referenced application, Applicants submit the
following:

1. Copy of the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosures;
2. Paper copy of Sequence Listing;
3. Computer-readable copy of Sequence Listing on diskette;
4. Statement Under 37 C.F.R. § 1.821-1.825;
5. A Petition for One Month Extension of Time;
6. A check in the amount of \$55.00 for Extension of Time; and
5. Return receipt postcard.

The Commissioner is hereby authorized to charge any under-payments or credit
any over-payments to our Deposit Account No. 06-1448.


Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Sequence Listing, Assistant Commissioner for Patents, Washington, DC 20231 on the date set forth below:


November 19, 2001
Date

Devora L. Gavel

Respectfully submitted,
FOLEY, HOAG & ELIOT LLP


Jennifer K. Holmes, Ph.D.
Reg. No. 46,778
Attorney for Applicants
Customer ID No. 25181

RECEIVED
FEB 05 2002
TECH CENTER 1600/2900


FEB 07 2002
FEB 07 2002
FEB 07 2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Please see CRF Problem Report.

RECEIVED

FEB 05 2002

TECH CENTER 1600/2900

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
 - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
 - Email: PATIN21HELP@uspto.gov
 - To purchase PatentIn software: (703) 306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE